60 DEGREES PHARMACEUTICALS, INC.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 |
|---|---|---|---|---|
| Revenue | $1.0M | $607,574 | $253,573 | $223,208 |
| Gross profit | $223,776 | $222,809 | -$220,977 | -$209,162 |
| Operating income | -$7.8M | -$9.7M | -$5.2M | -$1.8M |
| Operating expenses | $8.4M | $10.0M | $4.9M | $1.8M |
| Cost of revenue | $781,695 | $384,765 | $474,550 | $432,370 |
| Cash from operations | -$6.8M | -$5.6M | -$4.5M | -$1.0M |
| Capital expenditure | $139,881 | $103,773 | $57,623 | — |
| Free cash flow | -$7.0M | -$5.8M | -$4.6M | — |
| Total assets | $5.4M | $5.8M | $7.8M | $1.3M |
| Total liabilities | $2.0M | $1.8M | $3.0M | $25.4M |
| Total debt | — | — | — | $3.0M |
Shares outstanding 2.7M · Free float 59.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.